guest ::
| Home > Publications Database > The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. > print |
| Home > Publications Database > The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. > print |
| 001 | 155430 | ||
| 005 | 20250415100045.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-021-05253-y |2 doi |
| 024 | 7 | _ | |a pmid:33677733 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC8175325 |2 pmc |
| 024 | 7 | _ | |a 0340-6997 |2 ISSN |
| 024 | 7 | _ | |a 1432-105X |2 ISSN |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 024 | 7 | _ | |a altmetric:101492017 |2 altmetric |
| 037 | _ | _ | |a DZNE-2021-00636 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ashton, N. J. |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2021 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1744633299_21648 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The development of blood biomarkers that reflect Alzheimer's disease (AD) pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests for dementia differential diagnosis and early detection. In 2019, the Geneva AD Biomarker Roadmap Initiative included blood biomarkers in the systematic validation of AD biomarkers.A panel of experts convened in November 2019 at a two-day workshop in Geneva. The level of maturity (fully achieved, partly achieved, preliminary evidence, not achieved, unsuccessful) of blood biomarkers was assessed based on the Biomarker Roadmap methodology and discussed fully during the workshop which also evaluated cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers.Plasma p-tau has shown analytical validity (phase 2 primary aim 1) and first evidence of clinical validity (phase 3 primary aim 1), whereas the maturity level for Aβ remains to be partially achieved. Full and partial achievement has been assigned to p-tau and Aβ, respectively, in their associations to ante-mortem measures (phase 2 secondary aim 2). However, only preliminary evidence exists for the influence of covariates, assay comparison and cut-off criteria.Despite the relative infancy of blood biomarkers, in comparison to CSF biomarkers, much has already been achieved for phases 1 through 3 - with p-tau having greater success in detecting AD and predicting disease progression. However, sufficient data about the effect of covariates on the biomarker measurement is lacking. No phase 4 (real-world performance) or phase 5 (assessment of impact/cost) aim has been tested, thus not achieved. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Alzheimer’s disease |2 Other |
| 650 | _ | 7 | |a Aβ40 |2 Other |
| 650 | _ | 7 | |a Aβ42 |2 Other |
| 650 | _ | 7 | |a Blood |2 Other |
| 650 | _ | 7 | |a P-tau |2 Other |
| 650 | _ | 7 | |a Strategic roadmap |2 Other |
| 650 | _ | 7 | |a Amyloid beta-Peptides |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a Peptide Fragments |2 NLM Chemicals |
| 650 | _ | 7 | |a tau Proteins |2 NLM Chemicals |
| 650 | _ | 2 | |a Alzheimer Disease: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Peptides |2 MeSH |
| 650 | _ | 2 | |a Biomarkers |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Peptide Fragments |2 MeSH |
| 650 | _ | 2 | |a Tomography, X-Ray Computed |2 MeSH |
| 650 | _ | 2 | |a tau Proteins |2 MeSH |
| 700 | 1 | _ | |a Leuzy, A. |b 1 |
| 700 | 1 | _ | |a Karikari, T. K. |b 2 |
| 700 | 1 | _ | |a Mattsson-Carlgren, N. |b 3 |
| 700 | 1 | _ | |a Dodich, A. |b 4 |
| 700 | 1 | _ | |a Boccardi, M. |0 P:(DE-2719)9000492 |b 5 |
| 700 | 1 | _ | |a Corre, J. |b 6 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-2719)2811239 |b 7 |
| 700 | 1 | _ | |a Nordberg, A. |b 8 |
| 700 | 1 | _ | |a Ossenkoppele, R. |b 9 |
| 700 | 1 | _ | |a Zetterberg, H. |b 10 |
| 700 | 1 | _ | |a Blennow, K. |b 11 |
| 700 | 1 | _ | |a Frisoni, Giovanni B |0 P:(DE-2719)9001538 |b 12 |u dzne |
| 700 | 1 | _ | |a Garibotto, V. |b 13 |
| 700 | 1 | _ | |a Hansson, O. |b 14 |
| 773 | _ | _ | |a 10.1007/s00259-021-05253-y |g Vol. 48, no. 7, p. 2140 - 2156 |0 PERI:(DE-600)2098375-X |n 7 |p 2140 - 2156 |t European journal of nuclear medicine and molecular imaging |v 48 |y 2021 |x 1619-7089 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/155430/files/DZNE-2021-00636.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/155430/files/DZNE-2021-00636.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:155430 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)9000492 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 7 |6 P:(DE-2719)2811239 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)9001538 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 2 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-23 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-23 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2021 |d 2022-11-23 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b EUR J NUCL MED MOL I : 2021 |d 2022-11-23 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-02-02 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-23 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-23 |
| 920 | 1 | _ | |0 I:(DE-2719)5000062 |k AG Boccardi |l Implementation Neuroscience |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)6000017 |k Rostock / Greifswald common |l Rostock / Greifswald common |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000062 |
| 980 | _ | _ | |a I:(DE-2719)6000017 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|